Key facts
- It has raised $2.0M; the latest was Early Stage VC ($2.0M) in Aug 2025.
- Notable investors include Mosaic Venture Lab.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Taiwan Universe BioMedicine
- ·The full record, as it builds
Funding rounds
No funding rounds for Taiwan Universe BioMedicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Taiwan Universe BioMedicine
Developer of virus-like particle (VLP) and bivalent enterovirus vaccines focused on advancing non-invasive immunization technologies. The company specailises in bivalent enterovirus vaccines, seasonal influenza VLP vaccines, antigen design platforms, molecular assembly systems, immunogenicity enhancement tools, clinical trial support, and cross-disease vaccine expansion strategies, enabling safer, more effective, and scalable vaccine development for public health applications.
- Sector
- Healthcare
- HQ
- Taiwan
- Founded
- 2023
- Website
- taiutw.com/
- Ownership
- Privately Held (backing)
Taiwan Universe BioMedicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Taiwan Universe BioMedicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Taiwan Universe BioMedicine in its N-PORT filings yet. We sweep new filings monthly.